Indication: Gastric Cancer

A Phase 3, double-blind, randomized study of BGB 290 versus placebo as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum-based first-line chemotherapy / BGB-290-303

Inoperable Locally Advanced or Metastatic

Sub-indication: Gastric Metastatic or Locally advanced, HER 2 neg

Line of Therapy: second line

Drug study

Principal Investigator: Michael Driscoll, M.D.
Norton Cancer Institute

Sponsor: BeiGene, Ltd

Learn more at ClinicalTrials.gov

Email for more information: GI-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.